Efinopegdutide, a GLP1R and glucagon receptor (GCGR) dual agonist, significantly reduced liver fat content in a dose-dependent manner in a phase II trial (NCT04944992) and has received FDA fast-track designation for NASH [150]. This evidence concerns the gene GCGR and metabolic dysfunction-associated steatohepatitis.